Ann: AVITA Medical to Announce First Quarter 2024 Results, page-34

First 34 Last

Share
Profile

Follow
PJL100

1,013 Posts.

171

14/05/24

13:37

Post #: 73816083
Share

Originally posted by DrS777: ↑

Good call if you listen to it. Mentioned that sales this Qtr are back to expected levels and that large number of VAC approvals expected this Qtr/Next. One of the 4million dollar costs was a one off with Permeaderm onboarding.

With ReCell Go approval end of the month it makes sense to wait for international roll out strategy with the new and best technology. ReCell Go inventory was confirmed as ready to go day 1.

As a anaesthetist, working closely with surgeons, my opinion is the uptake acceleration with ReCell Go is likely to be very significant, but of course JC is being conservative with projections which is smart as he has maybe overstepped the enthusiasm before and we get a run up of SP followed by a drop with any negative news. I can tell you that surgeons, like all humans, will always be attracted to "convenience". Less training, less OT time, excellent clinical results with less patient grafting = strong encouragement to adopt. The argument that the spray on skin cell suspensions are now standardised in Recell Go, rather than relying on physician manual disaggregation is also a much more scientific feel to it which as doctors, we like.

All still on track to becoming the global standard of care for a majority of SSG's across the developed world within a few years - and then Vitiligo on top, as well as wound synergies with dressings, wound scaffolds. Current Market Cap just a drop in the ocean of where this will be within a few short years. If this all works out as planned and this grows to become a ASX 100 company within a few years where will the SP be then? First major step is ReCell GO launch. Second major step is profitability in 2025.

Again, don't consider selling until profitability IMO. Certainly I will not nor any of my medical colleague that are holders and are firm believers we discuss this often and look forward to the Australian roll out.

Expand

thanks for the post and optimism , will the approval in Australia depend on TGA acceptance of the procedure?, globally does every country have a similar body to scan new medical treatments and if so are they as tedious and lengthy as FDA wait times?

AVH Price at posting: $2.74 Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

OJC

SPC to merge with Original Juice Co and Nature One Dairy

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

There are more pages in this discussion • 161 more messages in this thread...

First 34 Last

Add AVH (ASX) to my watchlist

(20min delay)
Last $2.99		Change -0.070(2.29%)		Mkt cap ! $210.5M

Open	High	Low	Value	Volume
$3.00	$3.05	$2.98	$259.6K	86.11K

Buyers (Bids)

No.	Vol.	Price($)
3	4898	$2.98

Sellers (Offers)

Price($)	Vol.	No.
$3.02	3305	1

View Market Depth

No.	Vol.	Price($)
3	4898	2.980
1	12	2.970
1	8873	2.960
3	2693	2.950
1	25	2.920

Price($)	Vol.	No.
3.020	3305	1
3.030	1180	2
3.050	15000	2
3.060	3827	4
3.070	12	1

Last trade - 16.10pm 02/10/2024 (20 minute delay)

AVH (ASX) Chart

Ann: AVITA Medical to Announce First Quarter 2024 Results, page-34

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

SPC to merge with Original Juice Co and Nature One Dairy

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: AVITA Medical to Announce First Quarter 2024 Results, page-34

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

SPC to merge with Original Juice Co and Nature One Dairy

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News